| Id: | acc0381 |
| Group: | 1sens |
| Protein: | STAT1 |
| Gene Symbol: | STAT1 |
| Protein Id: | P42224 |
| Protein Name: | STAT1_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr701 |
| Site Sequence: | ELDGPKGTGYIKTELISVSEV |
| Disease Category: | Cancer |
| Disease: | Meningioma |
| Disease Subtype: | malignant meningioma |
| Disease Cellline: | IOMM-Lee |
| Disease Info: | |
| Drug: | LB-100 |
| Drug Info: | "LB-100 is a protein phosphatase 2A (PP2A) inhibitor with IC50 values of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells, respectively. " |
| Effect: | modulate |
| Effect Info: | The PP2A inhibitor LB-100 inhibits the growth and invasion of malignant meningioma cells by enhancing the phosphorylation of STAT1. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 36203966 |
| Sentence Index: | 36203966_8 |
| Sentence: | "Notably, the PP2A inhibitor LB-100 increased the phosphorylation of STAT1, thereby increasing the expression of the immune checkpoint protein B7-H3 in malignant meningioma cells in vitro." |
Sequence & Structure:
MSQWYELQQLDSKFLEQVHQLYDDSFPMEIRQYLAQWLEKQDWEHAANDVSFATIRFHDLLSQLDDQYSRFSLENNFLLQHNIRKSKRNLQDNFQEDPIQMSMIIYSCLKEERKILENAQRFNQAQSGNIQSTVMLDKQKELDSKVRNVKDKVMCIEHEIKSLEDLQDEYDFKCKTLQNREHETNGVAKSDQKQEQLLLKKMYLMLDNKRKEVVHKIIELLNVTELTQNALINDELVEWKRRQQSACIGGPPNACLDQLQNWFTIVAESLQQVRQQLKKLEELEQKYTYEHDPITKNKQVLWDRTFSLFQQLIQSSFVVERQPCMPTHPQRPLVLKTGVQFTVKLRLLVKLQELNYNLKVKVLFDKDVNERNTVKGFRKFNILGTHTKVMNMEESTNGSLAAEFRHLQLKEQKNAGTRTNEGPLIVTEELHSLSFETQLCQPGLVIDLETTSLPVVVISNVSQLPSGWASILWYNMLVAEPRNLSFFLTPPCARWAQLSEVLSWQFSSVTKRGLNVDQLNMLGEKLLGPNASPDGLIPWTRFCKENINDKNFPFWLWIESILELIKKHLLPLWNDGCIMGFISKERERALLKDQQPGTFLLRFSESSREGAITFTWVERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAENIPENPLKYLYPNIDKDHAFGKYYSRPKEAPEPMELDGPKGTGYIKTELISVSEVHPSRLQTTDNLLPMSPEEFDEVSRIVGSVEFDSMMNTV
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| STAT1-Ser127 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -1.111 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | 0.281 | ||||||||
| LUAD | |||||||||
| LUSC | 0.829 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| STAT1-Ser162 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.117 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | -0.025 | ||||||||
| GBM | 1.015 | ||||||||
| HNSC | -0.463 | ||||||||
| LUAD | 0.053 | ||||||||
| LUSC | -1.995 | ||||||||
| non_ccRCC | 0.225 | ||||||||
| PDAC | |||||||||
| UCEC | 1.307 | ||||||||
| STAT1-Ser532 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -1.146 | ||||||||
| COAD | 0.265 | ||||||||
| HGSC | 2.521 | ||||||||
| ccRCC | -0.306 | ||||||||
| GBM | 0.079 | ||||||||
| HNSC | -0.783 | ||||||||
| LUAD | 0.212 | ||||||||
| LUSC | 0.216 | ||||||||
| non_ccRCC | -0.093 | ||||||||
| PDAC | -1.183 | ||||||||
| UCEC | 0.22 | ||||||||
| STAT1-Ser640 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | -0.628 | ||||||||
| GBM | 1.009 | ||||||||
| HNSC | 0.442 | ||||||||
| LUAD | -0.81 | ||||||||
| LUSC | -1.225 | ||||||||
| non_ccRCC | 1.22 | ||||||||
| PDAC | 0.93 | ||||||||
| UCEC | -0.939 | ||||||||
| STAT1-Ser708 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.707 | ||||||||
| COAD | |||||||||
| HGSC | 0.707 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| STAT1-Ser727 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.237 | ||||||||
| COAD | 0.528 | ||||||||
| HGSC | -2.013 | ||||||||
| ccRCC | -0.034 | ||||||||
| GBM | 1.48 | ||||||||
| HNSC | 0.35 | ||||||||
| LUAD | 0.26 | ||||||||
| LUSC | 0.618 | ||||||||
| non_ccRCC | -1.678 | ||||||||
| PDAC | 0.093 | ||||||||
| UCEC | 0.159 | ||||||||
| STAT1-Thr540 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | -0.707 |
| HGSC | 0.707 |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| Y | 701 | D | Melanoma | Phosphorylation | 17785551 |
| Y | 701 | U | Breast cancer/tumor/carcinoma | Phosphorylation | 24058806 |
| Y | 701 | U | Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome | Phosphorylation | 33815425 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -0.6427 | down | |
| P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -1.7733 | - | |
| P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -0.8673 | - | |
| P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -3.5049 | - | |
| P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -1.2234 | - | |
| P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -3.8772 | - | |
| P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -2.9951 | - | |
| P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -1.6009 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
